This report provides detailed information on the digital therapeutics market, covering the core and peripheral digital therapeutics solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade.
The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.
Digital therapeutics are clinically validated solutions that are delivered as applications, software and online programs, demonstrating the capability to facilitate positive outcomes when employed in the management of clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications.
The primary benefits of digital therapeutics include reduction of treatment related costs, generation and maintenance of personalized health data, reduction in stress amongst healthcare professionals, and increase in the adherence to prescribed treatment regimens. In addition, these digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population.
Currently, a wide variety of digital health applications and intuitive software are available for the aforementioned purposes. In fact, the COVID-19 pandemic has created a significant demand for remote healthcare solutions. Amidst other alternatives, digital therapeutics have emerged as a promising option since these can be employed as preventive or curative digital solutions for managing diverse target indications.
A recent survey highlighted that the percentage of patients adopting digital therapeutics in the US rose from 4.7% to 18%, post the pandemic outbreak, resulting in an increased prescription rate of such therapeutics. Presently, there are more than 40 USFDA approved digital therapeutic solutions available in the market, including apps, software and devices, for the management of numerous therapeutic areas, such as mental health disorders, substance use disorders and reproductive health.
It is worth noting that reSET, developed by Pear Therapeutics, was the first prescription digital therapeutics that received the USFDA approval in 2017. The application can be used as a method of opioid replacement therapy, increasing a patient's abstinence from substances of abuse during the treatment and enhancing the outpatient treatment program retention.
Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the digital therapeutics domain have witnessed a surge in the investment activity, with capital investments worth more than USD 9 billion.
According to the recent trends, various digital therapeutic companies are engaged in providing personalized solutions, along with remote access to medical care facilities, including a health coach. Further, taking into consideration both the historical and contemporary scenarios, we believe that the digital therapeutics market presents lucrative investment opportunities for both short and long-term investors.
Key Topics Covered:
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET 1.1. Analysis Notes 1.2. Innovator Landscape 1.3. Product Landscape 1.4. Value Proposition 1.5. Key Acquisition Targets 1.6. AI - AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS 2.1. Analysis Notes 2.2. Summary Dashboard 2.3. Capital Investments in Digital Therapeutics 2.4 AI - AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. BUSINESS RISK ANALYSIS 4.1. Analysis Notes 4.2. Business Risk Data 4.3. AI - AVII Appendices
5. MARKET FORECAST AND OPPORTUNITY ANALYSIS 5.1. Analysis Notes 5.2. Market Forecast and Opportunity Analysis: Summary 5.3. Market Forecast and Opportunity Analysis: Base Scenario 5.4. Market Forecast and Opportunity Analysis: Conservative Scenario 5.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
6. RETURN ON INVESTMENT 6.1. Analysis Notes 6.2. Estimated RoI for Investors in Company A 6.3. Estimated RoI for Investors in Company B 6.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Need for Digital Therapeutics and Innovators Landscape
5. THE DIGITAL THERAPEUTICS MARKET 5.1. Overview 5.2. Historical Milestones 5.3. Key Types of Solutions 5.4. Key Strategic Initiatives 5.5. Key Concepts, Marketed Products and Challenges
6. DIGITAL THERAPEUTICS: INNOVATOR LANDSCAPE 6.1. Methodology 6.2. Innovators in the Digital Therapeutics Market 6.3. Analysis of Competitive Landscape 6.4. Conclusion
7. DIGITAL THERAPEUTICS: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING 7.1. List of Digital Therapeutics 7.2. Analysis of Product Landscape 7.3. Health Indexing Methodology 7.4. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS 8.1. Overview and Methodology 8.2. Outreach-related Value 8.3. Developer Value 8.4. Product-related Value 8.5. Value to Patients 8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS 9.1. Overview and Methodology 9.2. Company Competitiveness Analysis
Section II Analysis of Investments
10. FUNDING AND INVESTMENT ANALYSIS 10.1. Overview 10.2. Analysis by Type of Funding 10.3. Analysis by Geography and Most Active Players 10.4. Analysis of Trends Across Various Funding Categories 10.5. Summary of Funding and Investments
Section III Financial Analysis and Assessment of Business Risks
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES 11.1. Fundamental Financial Analysis Overview 11.2. Financial Ratios (Interpretation Guide) 11.3. Case Study 1 11.4. Technical Financial Analysis Overview 11.5. Technical Indicators (Interpretation Guide) 11.6. Case Study 2
12. COMPANY PROFILES OF PUBLIC VENTURES 12.1 Akili Interactive 12.1.1. Key Highlights 12.1.1.1. Company Details 12.1.1.1. Company Overview 12.1.1.3. Insights from Balance Sheet 12.1.1.4. Management Team 12.1.1.5. Recent Developments 12.1.2. Key Financial Details 12.1.2.1. Company Investments 12.1.2.2. Company Fundamentals 12.1.2.3. Company Technicals 12.2. Better Therapeutics 12.2.1. Key Highlights 12.2.1.1. Company Details 12.2.1.1. Company Overview 12.2.1.3. Insights from Balance Sheet 12.2.1.4. Management Team 12.2.1.5. Recent Developments 12.2.2 Key Financial Details 12.2.2.1. Company Investments 12.2.2.2. Company Fundamentals 12.2.2.3. Company Technicals 12.3. Brain+ 12.3.1. Key Highlights 12.3.1.1. Company Details 12.3.1.1. Company Overview 12.3.1.3. Insights from Balance Sheet 12.3.1.4. Management Team 12.3.1.5. Recent Developments 12.3.2. Key Financial Details 12.3.2.1. Company Investments 12.3.2.2. Company Fundamentals 12.3.2.3. Company Technicals 12.4. Dario Health 12.4.1. Key Highlights 12.4.1.1. Company Details 12.4.1.1. Company Overview 12.4.1.3. Insights from Balance Sheet 12.4.1.4. Management Team 12.4.1.5. Recent Developments 12.4.2 Key Financial Details 12.4.2.1. Company Investments 12.4.2.2. Company Fundamentals 12.4.2.3. Company Technicals 12.5. Ehave 12.5.1. Key Highlights 12.5.1.1. Company Details 12.5.1.1. Company Overview 12.5.1.3. Insights from Balance Sheet 12.5.1.4. Management Team 12.5.1.5. Recent Developments 12.5.2. Key Financial Details 12.5.2.1. Company Investments 12.5.2.2. Company Fundamentals 12.5.2.3. Company Technicals 12.6. Mindcure 12.6.1. Key Highlights 12.6.1.1. Company Details 12.6.1.1. Company Overview 12.6.1.3. Insights from Balance Sheet 12.6.1.4. Management Team 12.6.1.5. Recent Developments 12.6.2. Key Financial Details 12.6.2.1. Company Investments 12.6.2.2. Company Fundamentals 12.6.2.3. Company Technicals 12.7. Newtopia 12.7.1. Key Highlights 12.7.1.1. Company Details 12.7.1.1. Company Overview 12.7.1.3. Insights from Balance Sheet 12.7.1.4. Management Team 12.7.1.5. Recent Developments 12.7.2. Key Financial Details 12.7.2.1. Company Investments 12.7.2.2. Company Fundamentals 12.7.2.3. Company Technicals 12.8. Pear Therapeutics 12.8.1. Key Highlights 12.8.1.1. Company Details 12.8.1.1. Company Overview 12.8.1.3. Insights from Balance Sheet 12.8.1.4. Management Team 12.8.1.5. Recent Developments 12.8.2. Key Financial Details 12.8.2.1. Company Investments 12.8.2.2. Company Fundamentals 12.8.2.3. Company Technicals 12.9. Sharecare 12.9.1. Key Highlights 12.9.1.1. Company Details 12.9.1.1. Company Overview 12.9.1.3. Insights from Balance Sheet 12.9.1.4. Management Team 12.9.1.5. Recent Developments 12.9.2 Key Financial Details 12.9.2.1. Company Investments 12.9.2.2. Company Fundamentals 12.9.2.3. Company Technicals
13. BUSINESS RISK ANALYSIS 13.1. Overview and Methodology 13.2. Operations-related Risks 13.3. Business-related Risks 13.4. Financial / Asset-related Risks 13.5. Product / Technology Risks 13.6. Other Risks 13.7. Business Risk Summary
Section IV Market Forecast and Opportunity Analysis
14. MARKET FORECAST 14.1. Overview and Methodology 14.2. Global Digital Therapeutics Market, 2023-2035 14.3. Distribution Across Key Market Segments
Section V Analysis of Returns on Investment and Key Acquisition Targets
15. ANALYSIS OF RETURNS ON INVESTMENT 15.1. Overview and Methodology 15.2. Case Studies
16. KEY ACQUISITION TARGETS 16.1. Overview 16.2. List of Key Acquisition Targets
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
